Barani Karikalan

With an emphasis on formulation stability, safety, and clinical compatibility, the current study sought to create and assess stable parenteral emulsions for critical care medicine. Three batches of emulsions were made using pharmaceutical-grade lipids, emulsifiers, and isotonic agents, and the results were compared to control formulations. During a 90-day storage period at 4 °C, 25 °C, and 40 °C, physicochemical parameters such as droplet size, zeta potential, pH, and osmolarity were measured. While statistical analyses (ANOVA and Levene's Test) confirmed reproducibility and consistency across batches, sterility and endotoxin testing guaranteed microbial safety. According to the results, emulsions kept at 4 °C exhibited the best stability, whereas emulsions kept at higher temperatures experienced mild or rapid destabilization. Endotoxin levels were within pharmacopeial limits, and all batches remained sterile. The feasibility of creating stable and safe parenteral emulsions that can be administered intravenously to critically ill patients is highlighted in the study, along with the significance of appropriate storage conditions in maintaining formulation integrity.

Liposomal drug delivery methods are becoming popular nanocarriers for anticancer drugs because they make the drugs more available, target them more accurately, and lower their toxicity in the body. The goal of this project was to improve cancer treatment results by designing, formulating, and testing liposomal systems that include a model chemotherapeutic drug. We used the thin-film hydration approach to make three liposomal formulations (F1, F2, and F3) and then measured their particle size, zeta potential, polydispersity index, and entrapment efficiency. Studies of drug release in vitro showed that the drugs were released over time, with F3 exhibiting the largest cumulative release (89% at 24 hours). The MTT assay showed that F3 dramatically reduced the viability of MCF-7 cells (to 12% at 50 µg/mL), making it better than both other formulations and the free medication. One-way ANOVA statistical analysis showed that there were substantial differences (p

Gorlin-Goltz syndrome (GGS) is a hereditary cancer syndrome with dominant inheritance caused by mutations in the PTCH1 gene, responsible for encoding a transmembrane receptor that interacts with the SHH signaling protein. This Hedgehog signaling pathway is essential for cell division and growth, for controlling the development of vertebrates' organs, for differentiating fingers, and for the formation of the brain, spinal cord, eyes, and teeth. When the PTCH gene is homozygously inactivated, cancerogenesis ensues, resulting in the development of numerous basal cell carcinomas and other neoplasms. Other than major anomalies such as multiple basal cell carcinomas, odontogenic keratocysts of the jaw, multiple palmar or plantar pits, bilamellar calcifications of falx cerebri and tentorium, Bifid or fused, or markedly splayed ribs, more than 100 minor anomalies have been described so far. Radiological investigations and genetic testing plays a major role in early diagnosis of this syndrome. We have presented a 19-year-old male patient who presented with multiple odontogenic keratocyst and eventually diagnosed to be GGS. we have also summarized GGS anomalies recorded so far along with differential diagnosis.